Viewing nowCombinationTwin Heat Tablet 40/10 mg
Telmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 13.87mg
Prescription medication · Combination
Keeps Biopharma Co., Ltd.

MFDS item code 201605773 · Approved 2016.09.30 · Insurance code 693201730
Treatment of essential hypertension not controlled with monotherapy
This medication is used as an additional treatment for patients with essential hypertension whose blood pressure is not adequately controlled with monotherapy of amlodipine or telmisartan. It helps to effectively lower blood pressure and reduce the risk of complications caused by hypertension. This drug dilates blood vessels, improves blood circulation, and reduces the burden on the heart. Therefore, it is used to improve blood pressure control in patients with essential hypertension.
The recommended dose is 1 tablet once daily, taken with water, with or without food. If possible, it is recommended that the tablet be taken at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, as follows, switching directly to this medicine may be considered. - 40/5 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or telmisartan 40 milligrams. - 80/5 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or this medicine 40/5 milligrams. - 40/10 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams. ○ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. For patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. Telmisartan is not removed by hemodialysis. ○ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 milligrams in patients with mild or moderate hepatic impairment. ◦ Elderly patients: The usual amlodipine regimen is recommended for elderly patients, but caution should be exercised when increasing the dose (see section ‘3. Patients requiring careful administration’). In patients aged 75 years or older, amlodipine clearance is reduced; therefore, start treatment at a low dose and increase the dose gradually.
○ Pediatric patients: As the safety and efficacy of this medicine have not been established in pediatric patients 18 years of age or younger, its use is not recommended.
This medication should not be taken during pregnancy, especially in the second and third trimesters, as it may pose a serious risk to the fetus. Patients with an allergy to any component of this drug, women who are pregnant or breastfeeding, and patients with severe liver impairment or certain heart diseases should not take this medication. Patients with poor liver function, gastrointestinal diseases, kidney diseases, and the elderly should use this drug with caution, and dosage adjustments may be necessary. During treatment with this medication, side effects such as dizziness, edema, and hypotension may occur; if symptoms persist or worsen, consult a physician. As this drug has a blood pressure lowering effect, patients with low fluid or sodium levels are at risk of hypotension, so adequate hydration and salt intake are necessary before taking it. Additionally, this medication may increase potassium levels in the blood, so caution is advised when taken with potassium supplements or medications containing potassium. As this drug may affect kidney function, patients with kidney disease should regularly check their kidney function through blood tests. This medication may interact with other antihypertensive drugs or certain medications, so inform healthcare providers of any other medications being taken. Caution is required while driving or operating machinery due to the possibility of drowsiness or dizziness. In case of overdose, symptoms such as severe hypotension or heart problems may occur, requiring immediate medical attention. This medication is not recommended for children and adolescents under 18 years of age due to insufficient safety and efficacy data. Store this medication out of reach of children, and keep it in its original packaging.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light and should be stored in a light-protective, airtight container. It is recommended to maintain a storage temperature between 1 to 30 degrees Celsius.
A white and light gray, biconvex oval double tablet
30 tablets (10 tablets/PTPX3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 13.87mg
Prescription medication · Combination
Keeps Biopharma Co., Ltd.
CombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 13.87mg
Prescription medication · Combination
Dasan Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Dasan Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 334.72mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Dasan Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 334.72mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Bivozon Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Vivozon Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 13.87mg
Prescription medication · Combination
Bivozon Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 13.87mg
Prescription medication · Combination
CMG Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.